Cinctive Capital Management LP Takes $444,000 Position in Liquidia Co. (NASDAQ:LQDA)

Cinctive Capital Management LP bought a new position in Liquidia Co. (NASDAQ:LQDA - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 44,416 shares of the company's stock, valued at approximately $444,000. Cinctive Capital Management LP owned approximately 0.06% of Liquidia at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Liquidia by 1.5% during the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company's stock valued at $42,587,000 after buying an additional 43,352 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Liquidia by 144.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock valued at $3,903,000 after purchasing an additional 230,820 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Liquidia by 18.2% during the second quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company's stock valued at $2,496,000 after purchasing an additional 32,076 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Liquidia by 735.1% during the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company's stock valued at $1,402,000 after purchasing an additional 123,402 shares during the last quarter. Finally, Sapient Capital LLC purchased a new stake in shares of Liquidia in the third quarter worth about $1,336,000. Institutional investors own 64.54% of the company's stock.

Liquidia Stock Down 1.5 %

Shares of LQDA stock traded down $0.17 during mid-day trading on Wednesday, reaching $11.09. 920,299 shares of the company's stock traded hands, compared to its average volume of 973,584. Liquidia Co. has a 12 month low of $6.83 and a 12 month high of $16.99. The company has a market cap of $938.66 million, a P/E ratio of -6.80 and a beta of 0.22. The company's 50-day moving average price is $10.80 and its 200-day moving average price is $11.33.

Insider Buying and Selling at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the sale, the chief executive officer now directly owns 812,193 shares of the company's stock, valued at $9,023,464.23. This trade represents a 0.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rajeev Saggar sold 2,526 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $11.19, for a total value of $28,265.94. Following the transaction, the insider now owns 204,857 shares of the company's stock, valued at $2,292,349.83. This represents a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,007 shares of company stock worth $245,780. Company insiders own 30.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LQDA. Needham & Company LLC reissued a "buy" rating and issued a $19.00 price target on shares of Liquidia in a report on Thursday, November 14th. Bank of America lowered their target price on shares of Liquidia from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Tuesday, August 20th. Lifesci Capital initiated coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an "outperform" rating and a $30.00 target price on the stock. Raymond James raised shares of Liquidia from an "outperform" rating to a "strong-buy" rating in a research note on Monday, August 19th. Finally, BTIG Research lowered their target price on shares of Liquidia from $29.00 to $25.00 and set a "buy" rating on the stock in a research note on Monday, August 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Liquidia currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).